Trials / Completed
CompletedNCT04686591
Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects
A Phase I, Open-label Study of Absolute Bioavailability and Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]AZD9977 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 30 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Study to Assess the Absorption, Metabolism, and Excretion of \[14C\]AZD9977 after a Single-Dose Oral Administration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD9977 capsule 50 mg | 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles) |
| DRUG | [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL) | One 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL) |
| DRUG | [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq) | One 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq) |
Timeline
- Start date
- 2020-12-21
- Primary completion
- 2021-02-04
- Completion
- 2021-02-04
- First posted
- 2020-12-29
- Last updated
- 2021-03-09
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04686591. Inclusion in this directory is not an endorsement.